Pegloticase: a guide to its use in treatment-refractory chronic gout in the EU
- First Online:
- Cite this article as:
- Lyseng-Williamson, K.A. Drugs Ther Perspect (2013) 29: 155. doi:10.1007/s40267-013-0039-7
- 66 Downloads
Intravenous pegloticase (KRYSTEXXA®), a recombinant polyethylene glycol-conjugated form of uricase (a uric acid-specific enzyme lacking in humans), is a novel approach to treating chronic gout refractory to conventional therapy. Pegloticase 8 mg every 2 weeks provides sustained reductions in plasma uric acid levels to less than the therapeutic target of 6 mg/dL (360 μmol/L) in a substantial proportion of patients with chronic refractory gout. The risk of infusion-related reactions can be minimized by following the recommended precautions, which include monitoring of serum uric acid levels.